TRNS
Transcat, Inc.
Industrial - Distribution
Market Cap$852M
5Y Perf.+252.9%
Build Your Comparison
Side-by-side financial analysisTRNS
TMO
Try popular comparisons:
Stock Comparison
TRNS vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$174.42B
5Y Perf.+29.5%
TRNS vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  TRNS |  TMO |
|---|---|---|
| Industry | Industrial - Distribution | Medical - Diagnostics & Research |
| Market Cap | $852M | $174.42B |
| Revenue (TTM) | $333M | $45.20B |
| Net Income (TTM) | $7M | $6.86B |
| Gross Margin | 32.6% | 39.4% |
| Operating Margin | 4.1% | 17.8% |
| Forward P/E | 51.9x | 18.9x |
| Total Debt | $129M | $40.85B |
| Cash & Equiv. | $5M | $9.86B |
TRNS vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TRNS
TMO
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Transcat, Inc. (TRNS) | 100 | 352.9 | +252.9% |
| Thermo Fisher Scien… (TMO) | 100 | 129.5 | +29.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TRNS vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Transcat, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇TMO emerged as the overall leader. Track its performance:
TRNS
Transcat, Inc.
The Growth Play
TRNS is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 19.2%, EPS growth -63.7%, 3Y rev CAGR 12.9%
- 7.7% 10Y total return vs TMO's 219.0%
- Lower volatility, beta 1.35, Low D/E 42.9%, current ratio 2.33x
Best for: growth exposure and long-term compounding
TMO
Thermo Fisher Scientific Inc.
The Income Pick
TMO carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 8 yrs, beta 0.91, yield 0.4%
- Beta 0.91, yield 0.4%, current ratio 1.89x
- Lower P/E (18.9x vs 51.9x)
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  TRNS | 19.2% revenue growth vs TMO's 3.9% |
| Value |  TMO | Lower P/E (18.9x vs 51.9x) |
| Quality / Margins | TMO | 15.2% margin vs TRNS's 2.0% |
| Stability / Safety | TMO | Beta 0.91 vs TRNS's 1.35 |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | TRNS | +17.9% vs TMO's +13.4% |
| Efficiency (ROA) | TMO | 6.4% ROA vs TRNS's 1.4%, ROIC 7.5% vs 2.6% |
TRNS vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
TRNS vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTMOLAGGINGTRNS
TRNSTranscat, Inc.
1leads
TMOThermo Fisher Scienti…
4leads
6 Total Categories
CATEGORYLEADERvs TRNSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TMO5/6
Valuation MetricsMultiples, price ratios, and targets
TMO4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TMO6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TRNS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
TMO1/1
Income & Cash Flow (Last 12 Months)
TMO leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 135.9x TRNS's $333M. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to TRNS's 2.0%. On growth, TRNS holds the edge at +15.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TRNSTranscat, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $333M | $45.2B |
| EBITDAEarnings before interest/tax | $40M | $10.5B |
| Net IncomeAfter-tax profit | $7M | $6.9B |
| Free Cash FlowCash after capex | $20M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +32.6% | +39.4% |
| Operating MarginEBIT ÷ Revenue | +4.1% | +17.8% |
| Net MarginNet income ÷ Revenue | +2.0% | +15.2% |
| FCF MarginFCF ÷ Revenue | +5.9% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.8% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.3% | +11.3% |
TMO leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
TMO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 26.5x trailing earnings, TMO trades at a 83% valuation discount to TRNS's 160.1x P/E. On an enterprise value basis, TMO's 18.9x EV/EBITDA is more attractive than TRNS's 24.8x.
| Metric | TRNSTranscat, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $852M | $174.4B |
| Enterprise ValueMkt cap + debt − cash | $976M | $205.4B |
| Trailing P/EPrice ÷ TTM EPS | 160.11x | 26.46x |
| Forward P/EPrice ÷ next-FY EPS est. | 51.85x | 18.88x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.53x |
| EV / EBITDAEnterprise value multiple | 24.76x | 18.86x |
| Price / SalesMarket cap ÷ Revenue | 2.57x | 3.91x |
| Price / BookPrice ÷ Book value/share | 2.83x | 3.31x |
| Price / FCFMarket cap ÷ FCF | 43.60x | 27.72x |
TMO leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
TMO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $2 for TRNS. TRNS carries lower financial leverage with a 0.43x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), TMO scores 6/9 vs TRNS's 5/9, reflecting solid financial health.
| Metric | TRNSTranscat, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | +2.2% | +13.2% |
| ROA (TTM)Return on assets | +1.4% | +6.4% |
| ROICReturn on invested capital | +2.6% | +7.5% |
| ROCEReturn on capital employed | +3.3% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.43x | 0.76x |
| Net DebtTotal debt minus cash | $124M | $31.0B |
| Cash & Equiv.Liquid assets | $5M | $9.9B |
| Total DebtShort + long-term debt | $129M | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | 2.81x | 5.89x |
TMO leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TRNS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TRNS five years ago would be worth $16,632 today (with dividends reinvested), compared to $10,136 for TMO. Over the past 12 months, TRNS leads with a +17.9% total return vs TMO's +13.4%. The 3-year compound annual growth rate (CAGR) favors TRNS at -0.3% vs TMO's -3.3% — a key indicator of consistent wealth creation.
| Metric | TRNSTranscat, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | +59.7% | -20.7% |
| 1-Year ReturnPast 12 months | +17.9% | +13.4% |
| 3-Year ReturnCumulative with dividends | -1.0% | -9.5% |
| 5-Year ReturnCumulative with dividends | +66.3% | +1.4% |
| 10-Year ReturnCumulative with dividends | +769.1% | +219.0% |
| CAGR (3Y)Annualised 3-year return | -0.3% | -3.3% |
TRNS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TRNS and TMO each lead in 1 of 2 comparable metrics.
Risk & Volatility
TMO is the less volatile stock with a 0.91 beta — it tends to amplify market swings less than TRNS's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TRNS currently trades 96.3% from its 52-week high vs TMO's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TRNSTranscat, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.35x | 0.91x |
| 52-Week HighHighest price in past year | $94.76 | $643.99 |
| 52-Week LowLowest price in past year | $50.23 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +96.3% | +72.9% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 50.8 |
| Avg Volume (50D)Average daily shares traded | 155K | 2.0M |
Evenly matched — TRNS and TMO each lead in 1 of 2 comparable metrics.
Analyst Outlook
TMO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates TRNS as "Buy" and TMO as "Buy". Consensus price targets imply 35.4% upside for TRNS (target: $124) vs 27.8% for TMO (target: $600). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | TRNSTranscat, Inc. | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $123.60 | $599.70 |
| # AnalystsCovering analysts | 10 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 0 | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +1.7% |
TMO leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TMO leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). TRNS leads in 1 (Total Returns). 1 tied.
Best OverallThermo Fisher Scientific In… (TMO)Leads 4 of 6 categories
Loading custom metrics...
TRNS vs TMO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is TRNS or TMO a better buy right now?
For growth investors, Transcat, Inc.
(TRNS) is the stronger pick with 19. 2% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 5x trailing P/E (18. 9x forward), making it the more compelling value choice. Analysts rate Transcat, Inc. (TRNS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TRNS or TMO?
On trailing P/E, Thermo Fisher Scientific Inc.
(TMO) is the cheapest at 26. 5x versus Transcat, Inc. at 160. 1x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 18. 9x.
03Which is the better long-term investment — TRNS or TMO?
Over the past 5 years, Transcat, Inc.
(TRNS) delivered a total return of +66. 3%, compared to +1. 4% for Thermo Fisher Scientific Inc. (TMO). Over 10 years, the gap is even starker: TRNS returned +769. 1% versus TMO's +219. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TRNS or TMO?
By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.
(TMO) is the lower-risk stock at 0. 91β versus Transcat, Inc. 's 1. 35β — meaning TRNS is approximately 49% more volatile than TMO relative to the S&P 500. On balance sheet safety, Transcat, Inc. (TRNS) carries a lower debt/equity ratio of 43% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — TRNS or TMO?
By revenue growth (latest reported year), Transcat, Inc.
(TRNS) is pulling ahead at 19. 2% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -63. 7% for Transcat, Inc.. Over a 3-year CAGR, TRNS leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TRNS or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus 1. 6% for Transcat, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus 4. 0% for TRNS. At the gross margin level — before operating expenses — TMO leads at 37. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TRNS or TMO more undervalued right now?
On forward earnings alone, Thermo Fisher Scientific Inc.
(TMO) trades at 18. 9x forward P/E versus 51. 9x for Transcat, Inc. — 33. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TRNS: 35. 4% to $123. 60.
08Which pays a better dividend — TRNS or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. TRNS does not pay a meaningful dividend and should not be held primarily for income.
09Is TRNS or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91), +219. 0% 10Y return). Both have compounded well over 10 years (TMO: +219. 0%, TRNS: +769. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TRNS and TMO?
These companies operate in different sectors (TRNS (Industrials) and TMO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: TRNS is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.